Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981549 · ClinicalTrials.gov registry record · Phase 1
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
A Phase 1 study of Central Retinal Vein Occlusion, sponsored by The Emmes Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03981549 is a Phase 1 study of Central Retinal Vein Occlusion that has completed, run by The Emmes Company. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03981549, a Phase 1 study of Central Retinal Vein Occlusion, has completed, sponsored by The Emmes Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months later. Participants will be followed for a total of 1 year.
Conditions Studied
Interventions
- BIOLOGICAL Autologous Bone Marrow CD34+ Stem Cells
- BIOLOGICAL Sham Therapy
Study Locations (1)
California
- Department of Ophthalmology & Vision Science, University of California Davis Eye Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-10-22 |
| Est. Completion | 2023-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03981549
The ClinicalTrials.gov registry entry for NCT03981549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Emmes Company, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Retinal Vein Occlusion appearing as the primary indexed condition, and to 2 interventions - of which Autologous Bone Marrow CD34+ Stem Cells is the first listed.
NCT03981549 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03981549 about?
NCT03981549 is a clinical study titled "Treatment of Central Retinal Vein Occlusion Using Stem Cells Study". This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, whi...
What is the current status of trial NCT03981549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-10-22. Estimated completion is 2023-11-09.
What conditions does trial NCT03981549 study?
This clinical trial studies the following conditions: Central Retinal Vein Occlusion.
What interventions are being tested in trial NCT03981549?
The interventions under investigation include: Autologous Bone Marrow CD34+ Stem Cells (BIOLOGICAL), Sham Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03981549?
This trial is sponsored by The Emmes Company, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03981549 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Retinal Vein Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.